logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
A

Amit G. Pandya

university of massachusetts system
H指数:61
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies

乌帕替尼在成人和青少年中治疗非节段性白癜风的疗效与安全性（Viti-Up）：两项III期随机对照研究的结果

The Lancet
IF88.5
2026-08-130
OAAI
Thierry Passeron; Vimal H Prajapati; Raja K Sivamani; Khaled Ezzedine; Nanja van Geel; Iltefat Hamzavi; Amit G Pandya; David Rosmarin; Leihong Xiang; Tamio Suzuki; Seemal Desai; Mehdi Rashighi; Smitha Suravaram; Irina Fish; Xiaofei Hu; Xiaoqiang Wu; Minglu Wang; Yao Yu; Ahmed M Soliman; Heidi S Camp
Assessment of vitiligo in clinical practice: a cross-sectional survey among experts

白癜风临床评估：一项针对专家的横断面调查

Journal of Dermatological Treatment
IF3.9
2025-10-100
OA
Jolien Duponselle; Marlide R. Jukema; Albert Wolkerstorfer; Khaled Ezzedine; Iltefat Hamzavi; Julien Seneschal; Viktoria Eleftheriadou; Amit G. Pandya; Amit Garg; Anand Ganesan; Boon Kee Goh; Davinder Parsad; Deepti Ghia; David Rosmarin; Giovanni Leone; Henry W. Lim; Hyun Jeong Ju; Jung Min Bae; John Ferguson; Laila Benzekri; Marwa Abdallah; Markus Böhm; Mauro Picardo; Mehdi Rashighi; M. Ramam; Michelle Rodrigues; Noufal Raboobee; Phyllis Spuls; Samia Esmat; Steven Tien Guan Thng; Thierry Passeron; Victor Huang; Reinhart Speeckaert; Nanja van Geel
Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib in patients with extensive vitiligo in a phase 2, randomized, double-blinded, dose-ranging, placebo-controlled study

口服Janus kinase 1抑制剂povorcitinib在广泛性白癜风患者中的疗效与安全性：一项2期、随机、双盲、剂量范围探索、安慰剂对照研究

Journal of the American Academy of Dermatology
IF11.8
2025-06-130
OAAI
Amit G. Pandya; Khaled Ezzedine; Thierry Passeron; Nanja van Geel; Kurt Brown; Leandro L. Santos; Lois Erskine; Kofi Wagya; Andrew Blauvelt
Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2 , multicentre, randomised, double-blind, placebo-controlled, dose-ranging study (vol 73, 102655, 2024)

每日一次乌帕替尼与安慰剂在广泛型非节段性白癜风成人患者中的比较：一项第2期、多中心、随机、双盲、安慰剂对照、剂量范围研究（卷73，102655，2024）

ECLINICALMEDICINE
IF10
2025-04-010
OAAI
Passeron, Thierry; Ezzedine, Khaled; Hamzavi, Lltefat; van Geel, Nanja; Schlosser, Bethanee J.; Wu, Xiaoqiang; Huang, Xiaohong; Soliman, Ahmed M.; Rosmarin, David; Harris, John E.; Camp, Heidi S.; Pandya, Amit G.
Autologous cell harvesting device provides repigmentation and improves quality-of-life for patients with stable vitiligo lesions in a large and diverse patient population

自体细胞采集装置为患有稳定型白癜风病灶的大规模且多样化的患者群体提供了重新着色，并改善了其生活质量。

Journal of the American Academy of Dermatology
IF11.8
2025-03-280
OA
Amit G. Pandya; Bassel H. Mahmoud; Richard H. Huggins; Anand K. Ganesan; Nanette B. Silverberg; Girish Munavalli; Eduardo Weiss; Raheel Zubair; Karan Lal; J. Daniel Jensen; Maral Kibarian Skelsey; Navid Ezra; Robyn Siperstein; Claire Noell; Steven K. Grekin; Iltefat H. Hamzavi
Efficacy and Safety of Ruxolitinib Cream in Vitiligo by Patient Characteristic Subgroups: Descriptive Pooled Analysis From Two Phase 3 Studies

按患者特征亚组分析的鲁索替尼乳膏治疗白癜风的有效性和安全性：来自两项III期研究的描述性汇总分析

DERMATOLOGY AND THERAPY
IF4.2
2025-03-010
OAAI
Seneschal, Julien; Wolkerstorfer, Albert; Desai, Seemal R.; Grimes, Pearl; Ezzedine, Khaled; Pandya, Amit G.; Kornacki, Deanna; Wei, Shaoceng; Passeron, Thierry; Rosmarin, David
Effective and durable repigmentation for stable vitiligo: A randomized within- subject controlled trial assessing treatment with autologous skin cell suspension transplantation
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
IF11.8
2024-12-010
OAAI
Hamzavi, Iltefat H.; Ganes, Anand K.; Mahmoud, Bassel H.; Weiss, Eduardo; Ahmed, Ammar M.; Robinson, Deanne; Goldman, Mitchel P.; Munavalli, Girish; Kahn, Steven A.; Huang, Victor; Waibel, Jill; Desai, Alpesh; Elbuluk, Nada; Desai, Seemal; Pandya, Amit G.
Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study

每日一次upadacitinib与安慰剂治疗成人广泛性非节段性白癜风: 一项2期、多中心、随机、双盲、安慰剂对照、剂量范围研究

ECLINICALMEDICINE
IF10
2024-07-011
OAAI
Passeron, Thierry; Ezzedine, Khaled; Hamzavi, Iltefat; van Geel, Nanja; Schlosser, Bethanee J.; Wu, Xiaoqiang; Huang, Xiaohong; Soliman, Ahmed M.; Rosmarin, David; Harris, John E.; Camp, Heidi S.; Pandya, Amit G.

研究方向

暂未获取到该数据
K
Khaled Ezzedine
H 指数:71论文数:672被引数:1.9万
J
John E. Harris
H 指数:59论文数:334被引数:1.3万
I
Iltefat Hamzavi
H 指数:68论文数:526被引数:1.5万
T
Thierry Passeron
H 指数:60论文数:740被引数:1.4万
N
Nanja van Geel
H 指数:44论文数:188被引数:7,420
L
Linda S. Hynan
H 指数:71论文数:424被引数:2.3万
D
David Rosmarin
H 指数:35论文数:229被引数:5,051
J
Julien Sénéschal
H 指数:52论文数:470被引数:9,086
M
Mauro Picardo
H 指数:84论文数:529被引数:2.5万
A
Albert Wolkerstorfer
H 指数:38论文数:221被引数:6,506